The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the ...

"These results suggest cabozantinib should be a new treatment option for patients with previously treated extrapancreatic or pancreatic NETs." The study was also published simultaneously in the ...

Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a ...

The Alliance for Clinical Trials in Oncology today announced final results will be presented at ESMO 2024 from CABINET ...